FibroBiologics Compliant with All Nasdaq Listing Requirements

FibroBiologics (Nasdaq: FBLG) announced Nasdaq has confirmed the company meets all applicable continued-listing criteria, including the $2.5 million stockholders' equity and the $1.00 bid price requirements.

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced Nasdaq has confirmed the company meets all applicable continued-listing criteria, including the $2.5 million stockholders' equity and the $1.00 bid price requirements. The company resolved its compliance issues but will remain under one-year monitoring for both metrics.

FibroBiologics is a clinical-stage biotech with 270+ patents issued and pending; its common stock will continue trading on Nasdaq under FBLG.

Positive

• Nasdaq compliance confirmed, preserving Nasdaq listing
• Resolved equity and bid-price deficiencies: $2.5M equity and $1.00 bid price

Negative

• Company remains under one-year monitoring for equity and bid price

Argus Apr 21 session

-0.65% close to close Open Argus

Details

News Market Reaction – FBLG

On Apr 21, the first trading day after this news, FBLG closed 0.65% below the previous close.

Data tracked by StockTitan Argus for the Apr 21 session.

Key Figures

Patent portfolio: 270+ patents issued and pending Stockholders’ equity requirement: $2.5 million Bid price requirement: $1.00

Patent portfolio

270+ patents issued and pending

Described company’s intellectual property position

Stockholders’ equity requirement

$2.5 million

Nasdaq continued listing criterion met

Bid price requirement

$1.00

Nasdaq minimum bid price condition met

Historical Context

5 past events · Latest: Apr 10

5 events

1. Apr 10

   Preclinical data update

   24h Move

   -2.2%

   Presented thymus organoid platform restoring immune function in preclinical models.

2. Apr 02

   Financing completion

   24h Move

   -0.7%

   Closed $3M public offering with shares and warrants at $1.32.

3. Mar 31

   Financing pricing

   24h Move

   +0.8%

   Priced $3M best-efforts offering of common stock and warrants.

4. Mar 31

   Clinical manufacturing

   24h Move

   +0.8%

   Completed first CYWC628 batch under CGMP for Phase 1/2 DFU trial.

5. Mar 25

   Reverse stock split

   24h Move

   -16.5%

   Announced 1-for-20 reverse split to address Nasdaq bid-price rules.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq capital market, stockholders’ equity, bid price requirement

3 terms

nasdaq capital market regulatory

"continued listing on The Nasdaq Capital Market, including the $2.5 million..."

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

stockholders’ equity financial

"including the $2.5 million stockholders’ equity requirement and the $1.00..."

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

bid price requirement regulatory

"stockholders’ equity requirement and the $1.00 bid price requirement."

A bid price requirement is a rule that specifies the minimum price a buyer must offer per share when making an official purchase proposal, tender offer, auction bid, or similar transaction. It matters to investors because it sets a floor for negotiations and valuation—like a reserve price in an auction—ensuring bids meet regulatory, contract or market standards and helping shareholders and markets judge whether an offer is fair or likely to succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has confirmed that the Company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $2.5 million stockholders’ equity requirement and the $1.00 bid price requirement.

The Company has now successfully resolved its Nasdaq compliance issues but will remain subject to one-year monitoring periods for both stockholders’ equity and bid price compliance. FibroBiologics’ common stock will continue to be listed and trade on Nasdaq under the symbol “FBLG.”

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s intent or ability to maintain compliance with the applicable Nasdaq continued listing rules and the continued listing and trading of the Company’s shares of common stock on Nasdaq. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) FibroBiologics’ ability to manufacture its product candidates; and (e) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.  

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (FBLG) announce on April 20, 2026 about Nasdaq listing?

FibroBiologics confirmed it meets Nasdaq continued-listing criteria, avoiding delisting risk. According to the company, Nasdaq verified compliance with the $2.5 million stockholders' equity and $1.00 bid price requirements and will monitor both metrics for one year.

Does FibroBiologics' common stock remain listed and tradable under the symbol FBLG?

Yes, FibroBiologics' common stock will continue trading on Nasdaq under FBLG. According to the company, Nasdaq's confirmation of compliance allows the stock to remain listed while monitoring continues for one year.

What Nasdaq requirements did FibroBiologics meet to resolve compliance issues?

FibroBiologics met the $2.5 million stockholders' equity and $1.00 minimum bid price requirements. According to the company, Nasdaq confirmed both criteria were satisfied, resolving the prior compliance deficiencies.

How long will Nasdaq monitor FibroBiologics (FBLG) after confirming compliance?

Nasdaq will monitor the company for one year for both equity and bid price compliance. According to the company, successful monitoring is required to maintain continued compliance without further action.

What does Nasdaq compliance mean for FibroBiologics' investors and operations?

Nasdaq compliance maintains market access and helps avoid delisting-related disruption. According to the company, confirmation of equity and bid-price requirements supports continued trading under FBLG while one-year monitoring remains in place.